Eiger BioPharmaceuticals (EIGR) currently reports a P/E ratio of -0.17. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore Eiger BioPharmaceuticals's P/E ratio history and peer comparisons.

Eiger BioPharmaceuticals's P/E ratio of -0.17 is lower than the Healthcare sector average of 25.3. That is roughly 100.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Eiger BioPharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -0.17, EIGR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.17, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGR for alerts when major investors trade the stock.

Eiger BioPharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -0.17 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EIGR with unrelated industries.